<DOC>
	<DOCNO>NCT01777503</DOCNO>
	<brief_summary>The objective study compare reduced-dose prasugrel standard dose clopidogrel patient older 74 year ACS , include non-ST-elevation ( NSTEACS ) ST-elevation ( STEMI ) patient , undergo early PCI . The primary endpoint trial one-year composite ( all-cause ) death , myocardial infarction , stroke re-hospitalization due cardiovascular reason bleed .</brief_summary>
	<brief_title>The Elderly ACS II Trial</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Arteriosclerosis</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Prasugrel Hydrochloride</mesh_term>
	<criteria>Patients &gt; 74 year age hospitalize ACS , without STE , onset symptom previous 72 hour , candidate early PCI . STEMI patient may randomize upon first diagnosis , provide meet exclusion criterion . STEMI patient exceed 50 percent global population study Eligible NSTEACS patient may randomize coronary angiography . To eligible , NSTEACS patient must least one follow characteristic : elevate troponin level ; diabetes mellitus ; prior MI ; least one new ischemic episode standard treatment index hospitalization ; ACS due stent thrombosis . History stroke transient ischemic attack ( TIA ) Gastrointestinal genitourinary bleed clinical significance within 6 week prior randomization . Hemoglobin level admission &lt; 10 g/dl , unless consider secondary renal dysfunction know myelodysplasia . Secondary cause acute myocardial ischemia . Known current platelet count &lt; 90,000 cells/mL . Ongoing oral anticoagulant treatment INR know &gt; 1.5 time screen . Concomitant severe obstructive lung disease , malignancy neurologic deficit limit followup adherence study protocol . Participation phase another clinical research study involve evaluation another investigational drug device within 30 day prior randomization Inability give least verbal informed consent study . Contraindications use clopidogrel prasugrel per package leaflet .</criteria>
	<gender>All</gender>
	<minimum_age>75 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>acute coronary syndrome</keyword>
	<keyword>elderly</keyword>
	<keyword>percutaneous revascularization</keyword>
	<keyword>antiaggregant drug</keyword>
</DOC>